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Abstract: Nowadays, apart from having to know first-line Helicobacter pylori eradication regimens
well, we must also be prepared to face treatment failures. The aim of this review is to summarize the
role of rifabutin in the management of H. pylori infection. Bibliographical searches were performed in
PubMed. Data on resistance and efficacy of rifabutin-containing regimens on H. pylori eradication
were meta-analyzed. Mean H. pylori rifabutin resistance rate (39 studies, including 9721 patients)
was 0.13%; when studies only including patients naïve to H. pylori eradication treatment were
considered, this figure was even lower (0.07%). Mean H. pylori eradication rate (by intention-to-
treat) with rifabutin-containing regimens (3052 patients) was 73%. Respective cure rates for second-,
third-, fourth- and fifth-line therapies, were 79%, 69%, 69% and 72%. Most studies administered
rifabutin 300 mg/day, which seemed to be more effective than 150 mg/day. The ideal length of
treatment remains unclear, but 10–12-day regimens are generally recommended. Adverse events to
rifabutin treatment in H. pylori studies were relatively infrequent (15%), and severe adverse events
were exceptional (myelotoxicity was the most significant, although always reversible). In summary,
rifabutin-containing therapy represents an encouraging strategy generally restricted, at present, to
patients where previous (usually multiple) eradication regimens have failed.
Keywords: Helicobacter pylori; H. pylori; rifabutin; treatment; rescue
1. Introduction
Helicobacter pylori (H. pylori) is a worldwide infection that is the main cause not only
of gastritis, but also of peptic ulcer disease and gastric cancer [1]. The most commonly
used first-line therapies—combining a proton pump inhibitor (PPI) plus two antibiotics,
generally including clarithromycin and either amoxicillin or metronidazole—currently fail
in more than 20–30% of cases [2]. The major factor affecting our ability to eradicate H. pylori
infection is antibiotic resistance, mainly to clarithromycin, which is increasing in many
geographic areas [3].
At present, a rescue regimen including a quadruple combination of a PPI, bismuth,
tetracycline, and metronidazole is generally used as the optimal second-line approach
after initial H. pylori eradication failure [4–6]. However, this treatment fails to eradicate
the infection in at least 20% of cases [7–10]. In addition, this regimen is associated with a
high incidence of adverse events, is relatively complex, and many countries are currently
experiencing a general unavailability of tetracycline and/or bismuth. On the other hand,
quinolone-based rescue regimens, mainly including levofloxacin, achieve a mean eradica-
tion rate of only approximately 80%, probably due to the increasing H. pylori resistance to
quinolones [7–9,11–13].
Consequently, in some cases, H. pylori infection persists even after two or more
eradication treatments, and these patients constitute a therapeutic dilemma. Currently, a
standard third/fourth-line therapy is lacking, and international guidelines recommend
performing culture in these patients to select a rescue treatment according to microbial
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sensitivity to antibiotics, but this strategy is not practical [14]. Therefore, the evaluation of
drugs without cross-resistance to macrolides, nitroimidazole or quinolones as components
of retreatment combination therapies seems to be worthwhile [15,16].
Rifabutin is a rifamycin-S derivative, commonly used to treat Mycobacterium avium and
Mycobacterium intracellulare, also referred to as Mycobacterium avium-intracellulare complex
(MAC) in human immunodeficiency virus (HIV)-infected patients [17,18]. The in vitro
sensitivity of H. pylori to this antibiotic is high, and it does not share resistance to clar-
ithromycin, metronidazole or levofloxacin [15,16,19,20]. Furthermore, the selection of
resistant H. pylori strains has been low in experimental conditions. Consequently, rifabutin-
based rescue therapies represent a potential and attractive strategy for H. pylori eradication
failures [21].
The aim of the present review is to summarize the role of rifabutin in the manage-
ment of H. pylori infection. We will review the following topics: (1) rifabutin’s general
antimicrobial activity and mechanism of action; (2) pharmacokinetics and pharmacody-
namics of rifabutin; (3) prevalence of resistance of H. pylori to rifabutin; (4) efficacy of
rifabutin for H. pylori eradication; (5) optimization strategies aimed to increase the efficacy
of rifabutin-based therapies; (6) safety of rifabutin; and, finally, (7) limitations of rifabutin
for the treatment of H. pylori infection.
2. Bibliographic Search and Statistical Analysis
A systematic bibliographic search was performed to identify studies evaluating the
role of rifabutin in the management of H. pylori infection. An electronic search was con-
ducted in PubMed up to October 2020 using the following algorithm (all fields): rifabutin
AND (Helicobacter pylori OR H. pylori). In addition, the reference lists from the selected
articles were reviewed to identify additional studies of potential interest. Articles published
in any language were included.
For each study, the variables extracted evaluating the prevalence of rifabutin resistance
were as follows: author, year of publication, country, pre- or post-treatment setting, number
of patients, and resistance rate. On the other hand, the variables extracted evaluating the
efficacy of rifabutin-containing treatments for each study were: author, publication year,
country, therapy combination (drugs and doses), treatment duration, number of included
patients, number of (previous) failed treatments, type of (previous) failed treatments,
eradication rate, and adverse events rate.
The main outcome of interest was the successful eradication of H. pylori at least four
weeks after completion of treatment, as assessed by at least one reliable diagnostic method
(that is, histology, urea breath test or monoclonal stool antigen test); we excluded studies
that used only serology testing for the detection of H. pylori. Analysis of H. pylori eradication
efficacy was considered on an intention-to-treat basis (that is, including all eligible patients
enrolled in the study regardless of compliance with the study protocol; patients with
unevaluable data were assumed to have been unsuccessfully treated). Subanalyses of the
data were performed by number of previous failed treatments and by duration of the
rifabutin regimen.
Data of variables (including rifabutin resistance, efficacy, and safety of rifabutin-
containing regimens on H. pylori eradication) were combined using the generic inverse
variance method, which involves a weighted average of the effect estimates from the
individual studies. The meta-analysis was performed using Review Manager (Cochrane
Collaboration). If the results were homogeneous, a fixed effect model was used, and if the
results were heterogeneous (I2 > 50%), a random effect model (DerSimonian and Laird)
was applied.
3. Rifabutin General Antimicrobial Activity and Mechanism of Action
Rifabutin is structurally related to, and shares many of the properties of, rifampin
(rifampicin) [22]. Rifabutin has a broad spectrum of antimicrobial activity, against my-
cobacteria, a variety of gram-positive and gram-negative bacteria, Toxoplasma gondii, and
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Chlamydia trachomatis. It is also active against Mycobacterium leprae, Mycobacterium tuberculo-
sis, and atypical mycobacteria [22].
Rifabutin is generally more active in vitro than rifampicin against rifampicin-susceptible
isolates of M. tuberculosis. It is also active against some rifampicin-resistant isolates, al-
though there is substantial cross-resistance in vitro between the two drugs [23].
Rifabutin inhibits the β-subunit of H. pylori DNA-dependent RNA polymerase en-
coded by the rpoB gene [24]. Laboratory mutants of H. pylori, which are obtained after
multiple serial passages in vitro and exhibit amino acid exchanges in codons 524 to 545
or in codon 585 of the rpoB gene, are resistant to rifabutin [24–26]. As an example, a
low rate of resistance (0.24%) to rifabutin was noted in H. pylori strains isolated from 414
Japanese patients, and the only rifabutin resistant strain detected showed a point mutation
in the rpoB gene and was isolated from a patient with a history of rifampin treatment for
pulmonary tuberculosis [27].
It has been shown that past rifampicin usage is closely linked to high minimal in-
hibitory concentrations (MICs) of rifabutin and the prevalence of point mutations in rpoB
gene, suggesting a cross-resistance between both antibiotics [28]. Therefore, although
rifabutin is a potent candidate antibiotic for H. pylori eradication as a rescue option, careful
consideration must be given to rifampicin treatment history prior to H. pylori eradication
with rifabutin [25,28].
4. Pharmacokinetics and Pharmacodinamics of Rifabutin
Rifabutin is a highly lipid-soluble compound with a pKa of 6.9. It is well absorbed
when given orally and exhibits high tissue-to-plasma ratios [22]. High concentrations of
the drug are attained in all tissues, particularly those of the liver and lung [22].
Rifabutin is chemically stable at a wide pH range and its antibacterial activity is likely
not to be hampered by the acidic environment of the stomach [22,24,29,30]. In one in vivo
study performed in rats, the concentrations of rifabutin in gastric juice were 10 to 17 times
higher than in blood, indicating extensive secretion into the stomach [31].
Mean absolute bioavailability is about 20% after a single dose [23]. When rifabutin
is administered with food, its absorption is delayed but not decreased [23]. The apparent
volume of distribution is about 8 to 9 L/kg, and the extent of binding to plasma proteins
varies between 71% and 94% [23].
Rifabutin is extensively metabolized [23,32]. The mean plasma elimination half-life
ranges from 32 to 67 h [23]. Although the pharmacokinetic properties of rifabutin are
influenced by hepatic and renal impairment, dosage alteration is probably required only
in patients with severe renal or hepatic dysfunction [23]. Rifabutin metabolism in liver
microsomes may be inhibited by clarithromycin [33].
5. Resistance of H. pylori to Rifabutin
Antibiotic resistance to H. pylori is the main variable affecting the efficacy of current
therapeutic regimens, and it is increasing worldwide [3]. Rifabutin shows good intracellu-
lar activity against H. pylori [34]. H. pylori has proven to be highly susceptible in vitro to
rifabutin [23,24,29]. At present, the methodology to identify rifabutin resistance is mainly
based on microbiological testing. The in vitro MIC of rifabutin against H. pylori [22,29,35]
was remarkably lower than that found for amoxicillin, clarithromycin, and metronida-
zole [22,35].
Rifabutin is generally used to cure or prevent MAC disease in patients with advanced
HIV infection, and for this reason, the secondary resistance of H. pylori to rifabutin is likely
to be absent in the general healthy population [36]. Nevertheless, rifabutin resistance
has generally been reported only after the administration of high doses for extended
durations, such as those required for the treatment of mycobacterial infections. In this
respect, the efficacy of rifabutin-containing regimens to treat MAC infection appear to be
uninfluenced by prior prophylactic administration of the drug to patients with acquired
immune deficiency syndrome (AIDS) [23].
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The majority of rifampicin-resistant strains are isolated from patients after treatment
failures, suggesting that previous, unsuccessful attempts of eradication seem to be an impor-
tant risk factor for the development of rifabutin resistance and/or multiresistance [37,38].
In particular, some reports have documented the (exceptional) possibility of resistance to
rifabutin, which was largely explained by previous exposure to this antibiotic [28].
An important concern regarding widespread use of rifabutin for treatment of H. pylori
infection is the emergence of resistance in Mycobacterium tuberculosis. However, no correla-
tion has been reported between short-term use of rifabutin for treatment of non-tuberculosis
infections, such as those of H. pylori, and emergence of resistance [24,39]. Moreover, prior
experience has shown that the risk of development of antimicrobial resistance with H. pylori
is further reduced when it is used with another antimicrobial agent such as amoxicillin [40].
By analogy with clarithromycin resistance, it has been hypothesized that the presence
of multiple strains of H. pylori, resistant and/or susceptible to the same antibiotic, in the
same patient is possible [41]. Thus, several studies have reported the coexistence of the
strains of H. pylori that determine the mixed pattern in the same patient [42]. In addition,
the presence of H. pylori hetero-resistance between two biopsy sites (antrum and fundus)
was recently shown in one-third of patients with secondary resistance, suggesting the
necessity, in these cases, to perform an antimicrobial susceptibility test from both sites of
the stomach [43]. Some authors have assessed the relationship between the presence of
mixed infection of H. pylori and both antimicrobial susceptibility and virulence markers [44].
When different bacteria were isolated in the host, they showed a resistance to rifabutin
(10%) that was higher than that of bacteria in single infection (4%) [44].
A recent systematic review of studies, published from 2006 to 2009, on primary
H. pylori antibiotic resistance demonstrated that the prevalence rate of rifabutin resistance
was very low (1.4%), but only two studies were included in the analysis [45]. The preva-
lence of primary antibiotic resistance of H. pylori in 2008 and 2009 in 18 European countries
was assessed in another study, and the rate was 1.1% in adults [3]. More recently, in
2015, Ghotaslou et al. reviewed previous studies (published during the last six years)
about the H. pylori antibiotic resistance, and the rifabutin resistance rate was relatively
high (6.7%) [46]. However, in this review, rifampicin and rifabutin resistance rates were
not clearly separated; while both antibiotics are structurally related and share many prop-
erties [22], and there is substantial cross-resistance in vitro between the two drugs [23],
rifabutin is generally more active in vitro [23,38]. The highest (outlier) result was reported
in one study where H. pylori eradication treatment was previously prescribed and only 16
patients were included [47].
Finally, for the present review of the most up to date literature, we summarized in Table 1
all the studies that have evaluated H. pylori rifabutin resistance rates [3,24,25,27,28,38,41,47–78].
From these 39 studies, including a total of 9721 patients, an overall rifabutin resistance rate of
0.13% was calculated (Figure 1); however, when only studies including pre-treatment patients
(that is, naïve to H. pylori eradication treatment) were considered, this figure was even lower
(0.07%), as is summarized in Figure 2. Continuous audit of the resistance figures in several
populations is needed to keep rifabutin resistance information updated.
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Table 1. Resistance of H. pylori to rifabutin.





Heep [24] 1999 Germany Post (mostly) 81 0
Bock [48] 2000 Germany Post (R) 2 0
Pilotto [49] 2000 Italy Pre 87 0
Toracchio [41] 2005 Italy Pre 420 0
Toracchio [41] 2005 Italy Post (C and M; no R) 104 1
Marzio [50] 2006 Italy Pre 41 2.4
Marzio [50] 2006 Italy Post 51 4
Miehlke [51] 2006 Germany Pre 145 0.7
Miehlke [51] 2006 Germany Post (C and M; no R) 25 0
Borody [52] 2006 Australia Post 114 0
Suzuki [28] 2009 Japan Pre 48 0
Suzuki [28] 2009 Japan Post 46 17
Chisholm [53] 2007 UK Post (70%) 255 0.8
Glocker [38] 2007 Germany Post (R in some) 1585 1.4
Miehlke [47] 2008 Germany Post (R) 16 31
Goh [54] 2011 Malaysia Pre 90 2.2
Marzio [55] 2011 Italy Pre 46 2.2
Marzio [55] 2011 Italy Post 34 5.9
Nishizawa [27] 2011 Japan Pre and post 414 0.2
McNulty [56] 2012 UK Pre and post 169 0
Tay [57] 2012 Australia Post 306 2
Megraud(adults) [3] 2013 Europe Pre 1893 1.2
Megraud(children) [3] 2013 Europe Pre 311 0.3
O’Connor [58] 2013 Ireland Pre 85 0
Larsen [59] 2013 Norway Pre 102 0
Selgrad [60] 2013 Germany Pre 122 0.8
Selgrad [60] 2013 Germany Post 262 5
Seo [61] 2013 Korea - 91 7.7
Gosciniak [62] 2014 Poland Pre 165 0
Biernat [63] 2014 Poland Pre 50 0
Selgrad [64] 2014 Germany Pre 29 0
Selgrad [64] 2014 Germany Post 37 8
John [65] 2015 Qatar Pre 105 4.8
Di Giulio [66] 2016 Italy Pre 83 1.2
Mori [67] 2016 Japan Post 25 3.4
Ciccaglione [68] 2016 Italy Post 56 0
Sung [69] 2017 Korea Post 6 0
Hays [25] 2018 France Pre and post 1015 1
Siavoshi [70] 2018 Iran - 104 7.7
Choi [71] 2019 Korea Pre and post 31 0
Lee [72] 2019 Korea Pre 202 1.5
Kouitcheu M. [73] 2019 Cameroon Pre 140 0
Miftahussurur [74] 2019 Indonesia Pre 63 0
Miftahussurur [75] 2019 Indonesia Pre 105 0
Miftahussurur [76] 2019 Nepal & Bangladesh Pre 98 0
Graham [77] 2020 USA Pre 345 0
Hirata [78] 2020 Japan Post 18 0
Graham [77] 2020 USA Post 99 0
C: clarithromycin; M: metronidazole; R: rifabutin; Pre: pre-treatment (naïve) setting (that is, before H. pylori eradication has been
administered); Post: post-treatment setting (that is, when H. pylori eradication has been previously prescribed).
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Figure 1. Resistance of H. pylori to rifabutin including all patients (both pre- and post-treatment). 
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Pathogens 2021, 10, 15 7 of 29Pathogens 2021, 10, x FOR PEER REVIEW 7 of 27  
 
 
Figure 2. Resistance of H. pylori to rifabutin including only patients naïve to H. pylori eradication treatment. 
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Figure 2. Resistance of H. pylori to rifabutin including only patients naïve to H. pylori eradication treatment.
6. Efficacy of Rifabutin for H. pylori Eradication
In 2015, Liu et al. conducted a systematic review and meta-analysis of clinical trials for
eradication of H. pylori that included a treatment arm with a PPI, rifabutin, and amoxicillin.
Twenty-one studies were included, and the overall eradication rate was 70% (by intention-
to-treat) [79]. More recently, Gingold-Belfer et al. performed a systematic review of
prospective clinical trials (thus excluding retrospective studies) with a treatment arm
consisting of PPI, amoxicillin, and rifabutin, and a meta-analysis of randomized controlled
trials [80]. The pooled eradication success in the 33 studies selected for subjects treated
with rifabutin triple therapy was 71.8%.
Finally, for the present review, to the best of our knowledge the most updated in the
literature, all the studies that have evaluated the efficacy of rifabutin-containing regimens
for the treatment of H. pylori infection are summarized in Table 2 [19,20,36,39,41,47,48,51,
52,57,67–69,77,78,81–108]. Overall, from the 3052 patients treated with rifabutin-containing
regimens included in Table 2, a mean H. pylori eradication rate (by intention-to-treat
analysis) of 73% (95% confidence interval (CI), 69–78%) was calculated (Figure 3). In most
cases, rifabutin was administered at doses of 300 mg per day (either as 300 mg once a day or
as 150 mg twice daily). Duration of treatment was 7 to 14 days in most of the studies. Almost
all the protocols included patients with at least one previous H. pylori eradication attempt.
Type of previous (failed) H. pylori eradication treatment varied markedly depending on the
study, but in most of the cases included a first-line treatment with a PPI, clarithromycin,
and either amoxicillin or nitroimidazole.
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Table 2. Rifabutin-containing therapies for the eradication of H. pylori.















Perri [81] 1998 Italy
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
Pantoprazole 40 mg/12 h
7 28 ≥2 PPI-containing tx 79 7.1
Bock [48] 2000 Germany
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Lansoprazole 30 mg/12 h
7 12 1 PPI+A- and C-containing tx 58 0
Bock [48] 2000 Germany
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Lansoprazole 30 mg/12 h
7 5 2 PPI+A- and C-containing tx 80 0
Bock [48] 2000 Germany
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Lansoprazole 30 mg/12 h
7 2 3 PPI+A- and C-containing tx 100 0
Bock [48] 2000 Germany
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Lansoprazole 30 mg/12 h
7 6 ≥1 PPI+A- and C-containing tx 83 0
Perri [82] 2000 Italy
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
Pantoprazole 40 mg/12 h
7 25 2 (1) PPI+C+A(2) PPI+C+M, PPI+C+T 80 3
Perri [82] 2000 Italy
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h









Beales [83] § 2001 UK
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
14 10 2 C- and M-containing tx 60 -
Canducci [84] 2001 Italy
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
10 10 ≥3 - 70 10
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Perri [36] 2001 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/12 h
Pantoprazole 40 mg/12 h
10 45 ≥1 PPI+C+A, PPI+C+M, RBC+C 67 9
Perri [36] 2001 Italy
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
Pantoprazole 40 mg/12 h
10 45 ≥1 PPI+C+A, PPI+C+M, RBC+C 87 11
Gisbert [85] 2003 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
14 14 2 (1) PPI+C+A(2) Q, RBC+T+M 79 36
Wong [86] 2003 China
Rifabutin 300 mg/24 h
Levofloxacin 500 mg/24 h
Rabeprazole 20 mg/12 h
7 37 1 PPI+C+A, PPI+C+M,PPI+A+M 92 34
Wong [86] 2003 China
Rifabutin 300 mg/24 h
Levofloxacin 500 mg/24 h
Rabeprazole 20 mg/12 h
7 19 ≥2 C-containing tx (100%),M-containing tx (76%) 89 34
Gisbert [87] 2004 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
14 12 2 (1) PPI+C+A(2) RBC+T+M 67 -
Gisbert [87] 2004 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
14 2 2 (1) RBC+C+A(2) RBC+T+M 100 -
Qasim [88] 2005 Ireland
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
PPI/12 h
10 34 2 (1) PPI+C+A, PPI+C+M(2) PPI+C+A, PPI+C+M, Q 38 2.9
Toracchio [41] ¥ 2005 Italy
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Pantoprazole 40 mg/12 h
10 65 ≥1 - 78 1.5
Borody [52] 2006 Australia
Rifabutin 150 mg/24 h
Amoxicillin 1–1.5 g/8 h
Pantoprazole 80 mg/8 h
12 63 1 C-containing tx 92 40
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Table 2. Cont.















Borody [52] 2006 Australia
Rifabutin 150 mg/24 h
Amoxicillin 1–1.5 g/8 h
Pantoprazole 80 mg/8 h
12 67 ≥2 C-containing tx 90 40
Gisbert [89] 2006 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
10 20 2 (1) PPI+C+A(2) Q, RBC+T+M 45 60
Miehlke [51] § 2006 Germany
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Esomeprazole 20 mg/12 h
7 73
≥1 (24% 1 tx,








Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Pantoprazole 40 mg/12 h
10 92 2 (1) PPI+C+A(2) Q 61 2
Navarro-Jarabo
[91] 2007 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
7 45 1 PPI+C+A, PPI+C+M 44 44
Van der Poorten
[39] 2007 Australia
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
PPI/12 h
10 19 1 C-containing tx 95 10
Van der Poorten
[39] 2007 Australia
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
PPI/12 h
10 16 2 (1) C-containing tx(2) Q (42% of the cases) 64 10
Van der Poorten
[39] 2007 Australia
Rifabutin 150 mg/12 h




(2) Q (42% of the cases)
(3) Other
62 10
Gisbert [92] 2008 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
10-14 51 2 (1) PPI+C+A(2) Q, RBC+T+M, PPI+A+L 55 47
Gisbert [92] 2008 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
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Miehlke [47] ¥ 2008 Germany
Rifabutin 300 mg/24 h
Moxifloxacin 400 mg/24 h
Esomeprazole 40 mg/24 h
7 24 1 PPI+A, PPI+C, PPI+C+A,PPI+C+M, Q, PPI+A+L 78 30
Miehlke [47] ¥ 2008 Germany
Rifabutin 300 mg/24 h
Moxifloxacin 400 mg/24 h
Esomeprazole 40 mg/24 h
7 52 2 PPI+A, PPI+C, PPI+C+A,PPI+C+M, Q, PPI+A+L 90 30
Miehlke [47] ¥ 2008 Germany
Rifabutin 300 mg/24 h
Moxifloxacin 400 mg/24 h
Esomeprazole 40 mg/24 h
7 17 3 PPI+A, PPI+C, PPI+C+A,PPI+C+M, Q, PPI+A+L 69 30
Miehlke [47] ¥ 2008 Germany
Rifabutin 300 mg/24 h
Moxifloxacin 400 mg/24 h
Esomeprazole 40 mg/24 h
7 10 ≥4 PPI+A, PPI+C, PPI+C+A,PPI+C+M, Q, PPI+A+L 89 30
Sacco [93] 2009 Italy
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Esomeprazole 20 mg/12 h
10 19 1 PPI+A+Mx 84 0
Van Zanten [94] 2010 Canada
Rifabutin 300 mg/24 h
Amoxicillin 1 g/12 h
PPI/12 h
7 4 1 - 100 0
Van Zanten [94] 2010 Canada
Rifabutin 300 mg/24 h





(2) PPI+C+A, PPI+C+M, Q
50 0
Van Zanten [94] 2010 Canada
Rifabutin 300 mg/24 h







Zullo [95] 2010 Italy
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
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Tay [57] 2012 Australia
Rifabutin 150 mg/12 h
Amoxicillin 1 g/8 h
Ciprofloxacin 500 mg/12 h
Rabeprazole 20 mg/8 h
5-7 210 ≥1 (1) PPI+C+A +/- others(mostly PPI+C+M) 95 -
Tay [57] 2012 Australia
Rifabutin 150 mg/12 h
Bismuth 240 mg/6 h
Ciprofloxacin 500 mg/12 h
Rabeprazole 20 mg/8 h
7 69 ≥1 PPI+C+A +/- others (mostlyPPI+C+M) 94 -
Gisbert [96] 2012 Spain
Rifabutin 150 mg/12 h







Jeong [97] 2012 Korea
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
PPI/12 h
10 7 2 (1) PPI+C+A(2) Q 71 -
Fiorini [99] 2013 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/8 h
Esomeprazole 40 mg/12 h
12 105 ≥1 - 89 15
Ierardi [100] 2014 Italy
Rifabutin 150 mg/12 h
Minocycline 100 mg/12 h
Bismuth 120 mg/6 h
Rabeprazole 20 mg/12 h
10 21 2 (1) PPI+C+A, sequential(2) PPI+A+L 78 7.4
Lim [98] 2014 Korea
Rifabutin 150 mg/12 h
Amoxicillin 1 g/8 h
Lansoprazole 60 mg/12 h
7 27 2
(1) PPI+C+A
(2) Q 96 11
Lim [98] 2014 Korea
Rifabutin 150 mg/12 h
Amoxicillin 1 g/8 h
Lansoprazole 30 mg/12 h
7 32 2 (1) PPI+C+A(2) Q 78 31
Gisbert [101] # 2015 Spain
Rifabutin 150 mg/12 h
Clarithromycin 500 mg/12 h
Omeprazole 20 mg/12 h
10 7 2 (1) PPI+C+M(2) Q 14 71
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Gisbert [101] # 2015 Spain
Rifabutin 150 mg/12 h
Clarithromycin 500 mg/12 h






Ciccaglione [68] 2016 Italy
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Pantoprazole 20 mg/12 h
10 27 2 (1) PPI+C+A(2) PPI+A+M/L/Mx 67 0
Ciccaglione [68] 2016 Italy
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Pantoprazole 20 mg/12 h
Bismuth 240 mg/12 h
10 29 2 (1) PPI+C+A(2) PPI+A+M/L/Mx 97 0
Mori [67] 2016 Japan
Rifabutin 300 mg/24 h
Amoxicillin 500 mg/8 h
Esomeprazole 20 mg/8 h
10 12 2 (1) PPI+C+A(2) PPI+A+M 83 75
Mori [67] 2016 Japan
Rifabutin 300 mg/24 h
Amoxicillin 500 mg/8 h
Esomeprazole 20 mg/8 h
10 17 2 (1) PPI+C+A(2) PPI+A+M 94 94
Sung [69] 2017 Korea
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
PPI 20 mg/12 h
7-14 12 ≥3 - 50 18
Cosme [102] 2017 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
10 12 ≥1 - 58 17
Fiorini [20] 2018 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/12 h
Esomeprazole 40 mg/12 h
12 257 ≥1 - 83 18
Papastergiou [103] 2018 Greece
Rifabutin 150 mg/12 h
Amoxicillin 1 g/8 h
Esomeprazole 40 mg/12 h
7 2 0 (naïve) - 50 25
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Papastergiou [103] 2018 Greece
Rifabutin 150 mg/12 h
Amoxicillin 1 g/8 h
Esomeprazole 40 mg/12 h
7 2 ≥1 - 50 25
Ribaldone [105] 2019 Italy
Rifabutin 150 mg/12 h










Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Omeprazole 20 mg/12 h
10-14 64 2 (1) PPI+C+A(2) Q 56 45
Burgos-Santamaría
[106] 2019 Spain
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h








Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h








[106] # 2019 Spain
Rifabutin 150 mg/12 h
Clarithromycin 500 mg/12 h
Omeprazole 20 mg/12 h
10-14 13 2 (1) PPI+C+M(2) Q (or vice versa) 23 75
Burgos-Santamaría
[106] # 2019 Spain
Rifabutin 150 mg/12 h
Clarithromycin 500 mg/12 h
Omeprazole 20 mg/12 h
10-14 3 3
(1) PPI+C+M
(2) Q (or vice versa)
(3) PPI+C+L
67 75
Saracino [108] 2020 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/12 h
Esomeprazole 40 mg/12 h
12 119 1 - 58 46
Saracino [108] 2020 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/12 h
Esomeprazole 40 mg/12 h
12 66 2 - 56 46
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Saracino [108] 2020 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/12 h
Esomeprazole 40 mg/12 h
12 44 3 - 54 46
Saracino [108] 2020 Italy
Rifabutin 150 mg/24 h
Amoxicillin 1 g/12 h
Esomeprazole 40 mg/12 h
12 41 ≥4 - 24 46
Graham [77] 2020 USA
Rifabutin 50 mg/8 h
Amoxicillin 1 g/8 h
Omeprazole 40 mg/12 h
14 228 0 (naïve) - 84 36
Hirata [78] 2020 Japan
Rifabutin 150 mg/12 h
Amoxicillin 750 mg/12 h






Kalfus [107] 2020 USA
Rifabutin 150 mg/8 h
Amoxicillin 1 g/8 h
Omeprazole 40 mg/8 h
(Talicia® single capsule)
14 77 0 (naïve) - 77 51
Kuo [19] 2020 China
Rifabutin 150 mg/12 h
Amoxicillin 1 g/12 h
Esomeprazole 40 mg/12 h
10 40 ≥2 - 78 23
PPI: proton pump inhibitor (standard dose); Type of previous treatments: (1) indicates 1st line treatment, (2) indicates 2nd line treatment, and (3) indicates 3rd line treatment; Tx: treatments; C: clarithromycin;
A: amoxicillin; Q: bismuth quadruple therapy (PPI, bismuth, tetracycline, and nitroimidazole); RBC: ranitidine bismuth citrate; T: tetracycline; M: metronidazole; L: levofloxacin; Mx: moxifloxacin; S:
sitafloxacin. ¶ Intention-to-treat analysis. § Patients infected with H. pylori resistant to both clarithromycin and metronidazole/tinidazole. ¥ Patients infected with H. pylori resistant to both clarithromycin and
metronidazole/tinidazole, and susceptible to rifabutin. # Patients allergic to penicillin.
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Figure 3. Efficacy (intention-to-treat analysis) of rifabutin-containing therapies for the eradication of H. pylori.
Clinical experience with rifabutin for treatment of H. pylori infection has focused
mainly on patients in whom one or more courses of anti-H pylori treatment previously
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failed [7–9,109–111]. However, three recent studies evaluated the role of rifabutin in H.
pylori treatment naïve patients [77,103,107]. The meta-analysis of the efficacy (intention-
to-treat) of these studies (including only 307 patients) showed a mean eradication rate of
82% (95% CI, 76–88%). Ultimately, the place of rifabutin as a first-line regimen in anti-H.
pylori treatment will be determined by factors such as treatment success, adherence, cost,
and availability. For the time being, rifabutin may be considered for first-line treatment
in regions with high clarithromycin, metronidazole, and levofloxacin resistance (>15%) if
bismuth is unavailable [8]. Obviously, head-to-head comparisons against reliable, well-
established, and effective first-line regimens will expand efficacy and safety data and
further define the role of rifabutin in the treatment of H. pylori infections.
As previously noted, most of the studies included rescue regimens after at least one
previous eradication failure (Table 2). When only second-line rifabutin-containing therapies
administered to the 342 patients with one previous eradication failure were included, the
mean eradication rate was 79% (95% CI, 67–91%) (Figure 4). When efficacy of third-line
rifabutin-containing therapies for the eradication of H. pylori in patients with two previous
eradication failures was calculated (including 678 patients), the cure rate was lower (69%;
95% CI, 61–78%) (Figure 5), and similar results were obtained in fourth-line treatment
(256 patients; 69% cure rate; 95% CI, 50–88%). Finally, as a fifth-line rescue regimen
(including 306 patients), the rifabutin-containing regimen was still quite effective (72%;
95% CI, 67–77%).
Figure 4. Efficacy (intention-to-treat analysis) of second-line rifabutin-containing therapies for the eradication of H. pylori in
patients with one previous eradication failure.
It has been suggested that rifabutin efficacy decreases with increasing number of
previous (failed) therapies, perhaps due to patients who failed eradication therapy and pos-
sibly harbored H. pylori strains that were more refractory to eradication treatment [39,108].
Accordingly, in the meta-analysis by Gingold-Belfer et al. previously mentioned, treatment
success with rifabutin triple therapy was 82% in treatment-naïve patients, 73% in patients
receiving second-line treatment, and 64% when this regimen was prescribed as a third-line
regimen [80]. However, as summarized in Figure 6, where studies assessing the efficacy
of rifabutin in fourth-line regimens are included, quite favorable results may be obtained
even after three previous eradication failures. Thus, the mean eradication rate in this
scenario was approximately 70%. Accordingly, the efficacy of rifabutin treatment was not
significantly influenced by the number of previous treatment failures in a recent study:
eradication rates in patients with one, two, three, and four or more previous failures were
78.3%, 89.6%, 68.6%, and 88.9%, respectively (non-statistically significant differences) [47].
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Figure 5. Efficacy (intention-to-treat analysis) of third-line rifabutin-containing therapies for the eradication of H. pylori in
patients with two previous eradication failures.
Figure 6. Efficacy (intention-to-treat analysis) of fourth-line rifabutin-containing therapies for the eradication of H. pylori in
patients with three previous eradication failures.
Just a few studies have directly compared—that is, in the same protocol of H. pylori
eradication—rifabutin vs. other antibiotics [36,51,86,87,91,104]. Firstly, few studies have
compared a PPI, amoxicillin, and rifabutin triple combination with the commonly used
bismuth-containing quadruple regimen. Perri et al. [36] were the first to perform a random-
ized study where patients who failed eradication after standard triple therapy were treated
for 10 days with a PPI, amoxicillin, and rifabutin (300 mg/24 h), or with bismuth quadruple
therapy. On intention-to-treat analysis, eradication rates were 87% for rifabutin-containing
therapy and 67% for bismuth quadruple therapy (these differences being statistically sig-
nificant). More recent studies have shown better results with the rifabutin-triple [87] or
bismuth-quadruple [91,104,108] regimen. Finally, the rifabutin-levofloxacin regimen has
also been compared with the bismuth quadruple treatment for second-line treatment,
reporting similar high eradication rates (91%) and similar good compliance (>95%) [86].
Miehlke et al., compared the rifabutin regimen with other treatments different to the
bismuth-based quadruple regimen [51]. Patients infected with H. pylori strains resistant
to both clarithromycin and metronidazole were randomized to receive esomeprazole,
rifabutin, and amoxicillin for 7 days, or omeprazole 40 mg and amoxicillin 1000 mg, each
given three times daily for 14 days. Eradication rates (intention-to-treat) were 74% and
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70%, respectively. Therefore, they concluded that high-dose omeprazole/amoxicillin dual
regimen and rifabutin triple therapy are comparable for rescue therapy.
Finally, other studies directly compared rifabutin to levofloxacin as third-line therapy
for H. pylori. In a first study, a statistically significant superiority for the levofloxacin
regimen was shown, although it should be noted that the eradication rate of 45% for
rifabutin triple therapy in this study was surprisingly low [89]. In another study, on the
contrary, higher cure rates were achieved with the rifabutin regimen (in this case, it was the
eradication rate of the levofloxacin regimen, only 57%, which was unexpectedly low) [97].
Finally, it should be noted that rifabutin therapy was highly effective even when
applied to H. pylori infection with primary resistance to clarithromycin or metronidazole
(or both) [41,48,49,51,52,77,83,86], and even in patients with triple resistance to these two
antibiotics plus quinolones [20], which is the usual scenario after several eradication
therapy failures. In this respect, some authors evaluated, in the same study, different
regimens after failure of two or more eradication treatments and achieved a final (overall)
eradication rate of almost 100% [83,92,106,112–117]. This emphasizes the recommendation
that in designing a treatment strategy we should prescribe two or more therapies which, if
used consecutively, come as close to the 100% cure rate as possible [118]. In this respect,
the aforementioned studies underline the fact that a wider perspective of the benefits of
retreating H. pylori infection can be obtained if cumulative eradication rates, and not only
absolute figures, with successive retreatments are taken into account.
7. How to Optimize Rifabutin-Based Treatments for H. pylori
In this section we will review the optimization strategies aimed to increase the efficacy
of rifabutin-based H. pylori eradication therapies.
7.1. Rifabutin Dose and Frequency
Almost all studies administered rifabutin 300 mg/day for treating H. pylori infec-
tion. The H. pylori cure rate in some (few) studies prescribing rifabutin 150 mg/day was
only approximately 40–70% [36,108], although other studies reported higher eradication
rates [20,52,99]. A single randomized study directly compared both doses [36]: patients
were treated for 10 days with pantoprazole, amoxicillin, and rifabutin 150 mg once daily
or 300 mg once daily. Eradication rates were 67% in the rifabutin 150 mg group and
significantly higher (87%) in the rifabutin 300 mg group. On the other hand, other authors
showed that 12 days of half the dose of rifabutin (150 mg daily) in combination with
increasing frequency of dosing with amoxicillin (1 g/8 h) and pantoprazole (80 mg/8 h)
achieved an eradication rate as high as 91% [52]. Furthermore, by increasing the dosage
of amoxicillin to 1.5 g/8 h for 12 days, an excellent overall eradication rate (97%) was
achieved. These data suggest that frequent dosing of a high-dose amoxicillin and a double
dose PPI in the presence of low-dose rifabutin (150 mg daily) are critical in increasing the
efficacy of triple rifabutin-based therapy [52].
The incidence of adverse events is probably related to the rifabutin dose, with events
reported more frequently in patients treated with doses of ≥450 mg daily than in those
receiving 300 mg daily, and in those receiving 300 mg compared with 150 mg daily [23].
Finally, regarding the dose of amoxicillin, a meta-analysis by Gingold-Belfer et al.
found that treatment was more likely to be successful when daily amoxicillin dose was
≥3000 mg [80].
7.2. Duration of Treatment
The ideal length of treatment for the rifabutin regimen remains unclear. In some re-
ports, a 7-day course is equally efficacious compared to 10- to 14-day regimens, while others
have found that the 7-day duration dramatically reduced the efficacy, with eradication rates
at only 44% [91]. Although some studies have suggested that rifabutin treatment could be
more likely to be successful when treatment duration is 14 days [80], many other studies
have shown that therapy between 12 and 14 days has yielded results similar to the 10-day
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course and are likely to increase the incidence of adverse events [39]. Recently, a random-
ized controlled trial compared 10-day vs. 14-day eradication therapy with esomeprazole
20 mg/6 h, amoxicillin 500 mg/6 h, and rifabutin 300 mg/24 h [67]. Intention-to-treat
eradication rates were 83% for the 10-day group and 94% for the 14-day group, respectively.
Therapy was stopped due to adverse events in 8% and 29% of patients in the 10-day and
14-day groups, respectively. Therefore, the authors concluded that the 14-day therapy
resulted in successful eradication in over 90% of patients, but the 10-day treatment may be
enough to obtain a successful eradication rate, considering the tolerability of therapy [67].
Accordingly, from studies included in Table 2 and Figure 3, a mean H. pylori eradication
rate of 79% for the 14-day regimen was calculated, while the corresponding figure for the
10-day regimen was similar (73%). In summary, current evidence suggests that 10 days
may be more effective than 7 days, but no clear additional benefit has been shown with 14
days, which may increase the side effect burden [7,9,111].
7.3. Type and Dose of Antisecretory Drug
In a recent study, H. pylori-infected patients with two previous eradication fail-
ures were randomly assigned to receive either lansoprazole 30 mg/12 h or lansoprazole
60 mg/12 h, together with amoxicillin (1 g/8 h) and rifabutin (150 mg/12 h) for 7 days [98].
Eradication rates were higher in the high-dose PPI group (96% vs. 78%). Therefore, a
key factor to successful rescue therapy with rifabutin-amoxicillin-PPI regimen may be to
increase doses of PPI. Accordingly, in the meta-analysis by Gingold-Belfer et al., rifabutin
treatment was more likely to be successful when daily PPI dose was ≥80 mg [80].
In this same line, studies on rifabutin-based regimens with a potassium-competitive
acid blocker such as vonoprazan instead of PPIs may additionally improve the success
of the rifamycin-containing eradication therapy. In a recent study, patients who failed
H. pylori eradication by clarithromycin-based first-line, metronidazole-based second-line,
and sitafloxacin-based third-line therapies were prescribed vonoprazan (20 mg), amoxicillin
(750 mg), and rifabutin (150 mg) twice daily for 10 days, and H. pylori eradication was
confirmed in all patients (19/19; 100%) [78].
7.4. Addition of Bismuth
Bismuth has an additive effect with antibiotics, overcomes levofloxacin and clar-
ithromycin resistance, and its efficacy is not affected by metronidazole resistance [119,120].
In addition, bismuth is one of the few antimicrobials to which resistance is not devel-
oped [121,122]. Bismuth exerts its antibacterial action mainly by preventing bacterial
colonization and adherence to gastric epithelium and by binding toxins produced by
H. pylori [123]. In addition, bismuth decreases mucin viscosity, reduces the bacterial load,
and has a synergistic effect with antibiotics [119]. Therefore, combining bismuth and
rifabutin in the same regimen is suggested as a promising option.
A combination of a triple therapy with PPI-amoxicillin-rifabutin but adding bismuth
and thus converting this triple regimen into a quadruple one, has recently been evaluated,
with encouraging results [57,68,100]. Ciccaglione et al. reported that the addition of
bismuth to a triple therapy that included PPI, amoxicillin, and rifabutin in patients treated
for the third time for H. pylori infection, resulted in 30% therapeutic gain compared to
rifabutin-based triple therapy alone [68].
Finally, this bismuth-rifabutin regimen has recently been evaluated in the context of the
“European Registry on H. pylori Management” (Hp-EuReg), an international multicenter
prospective non-interventional registry starting in 2013 aimed to evaluate the decisions
and outcomes in H. pylori management by European gastroenterologists [124]. Thirty
European countries, with over 300 recruiters, are actively participating in this project,
where patients are managed and registered according to their routine clinical practice [10].
To assess the effectiveness of empirical rescue therapies on third and subsequent lines in
Europe, 1782 rescue treatments were evaluated in this registry. The effectiveness of the
Pathogens 2021, 10, 15 21 of 29
rifabutin-based quadruple regimen (that is, a PPI, rifabutin, amoxicillin, and bismuth) in
these very refractory cases was 59% (by intention-to-treat) [125].
7.5. All-in-One Single Capsule Including Omeprazole, Amoxicillin, and Rifabutin
A recent development is the 2019 approval by the United States Food and Drug
Administration (FDA) of a combination product (Talicia®; RedHill Biopharma, Raleigh,
NC, USA) containing omeprazole, rifabutin, and amoxicillin. This is the first and only FDA-
approved rifabutin-based H. pylori therapy. Potentially, it may improve patient compliance
with treatment because of its relative simplicity. In the “ERADICATE Hp2” trial, this
combination successfully eradicated H. pylori in 84% of patients compared to 58% of those
who received the same doses of omeprazole and amoxicillin, but without rifabutin [77].
The recommended dose for this product is four capsules taken three times daily for 14 days;
total daily doses are omeprazole 120 mg, rifabutin 150 mg, and amoxicillin 3 g.
A limitation of the aforementioned study is that it was only conducted in the United
States and excluded persons of Asian descent. The higher effectiveness of H. pylori eradi-
cation therapy reported in some studies in Asian populations is possibly due to genetic
factors. For example, CYP2C19 polymorphism associated with poor PPI metabolism is
more common in Asian populations [80]. This phenotype leads to higher serum PPI levels
and more potent gastric acid inhibition and may partially account for the superior eradica-
tion rate [126]. While this may lead to a higher bactericidal activity of amoxicillin, CYP2C19
polymorphism is unlikely to affect rifabutin efficacy, which is chemically stable at a wide
pH range [80].
8. Tolerability of Rifabutin
The overall incidence rate for the occurrence of at least one adverse event (51%) was
comparable to placebo (50%) in patients with AIDS treated prophylactically with rifabutin
300 mg daily [23]. Myalgia and taste perversion were, however, significantly more frequent
with rifabutin than with placebo [23]. Other reported adverse effects include rash (3%),
nausea/vomiting (0.4%), neutropenia (0.4%), anemia (0.4%) and, rarely, impairment of
liver function [23,127]. In studies where rifabutin is administered to treat non-H. pylori
infections, the rate of adverse events is reported as approximately 25–30% [79,80,128]. In
our updated meta-analysis of all studies including rifabutin (Table 2), mean rate of adverse
effects was 15% (95% CI, 14–17%) (Figure 7), which seems to be a reasonable figure when
compared with other well-established eradication regimens, such as the bismuth and non-
bismuth quadruple therapies [129]. Furthermore, severe adverse events with rifabutin are
exceptional; in a recent review [80], only one severe adverse event was reported (diabetic
ketoacidosis) [77].
Myelotoxicity is the most significant adverse event of rifabutin [130,131]. Overall, this
complication is rare and is far more likely when high dose (600 mg/day) and prolonged
duration therapy is used [130,131]. Although several cases of myelotoxicity have been
reported during H. pylori therapy [39,41,82,84,86,88,89,96,99], this adverse event was not
reported in most studies evaluating rifabutin for H. pylori infection. In the studies reporting
this complication, myelotoxicity was observed in 1.5% to 3% of patients [39,41,86,88,96],
although in some studies the incidence was higher [84,89]. In the meta-analysis by Gingold-
Belfer et al., neutropenia was addressed in 27 studies, of which 19 studies reported no
cases of neutropenia and eight studies reported at least one case; in total, only 17 patients
developed neutropenia across all studies [80].
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Figure 7. Adverse events of rifabutin-containing therapies.
All patients from the literature recovered from myelotoxicity uneventfully in just a few
days, although it took 15 days to normalize white cell count after rifabutin discontinuation
in one case [84]. In some cases, the myelotoxicity was clinically apparent with fever [39,84].
However, there are no reports of infection or other adverse outcomes related to reduced
white cell count, at least in the scenario of H. pylori treatment [39,41,82,84,86,88,89,96].
It has been suggested that during short-term rifabutin treatment blood cell count
should be checked at any suspicious symptom. Moreover, some authors have recom-
mended performing systematic blood controls in all patients receiving rifabutin, despite
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being asymptomatic [85,89]. However, others suggest that a practical approach may be to
check the full blood count only if fever or other signs of systemic toxicity occur.
Only a few studies have directly compared—in the same protocol—the safety of
rifabutin and other antibiotics in H. pylori eradication regimens. Firstly, some studies have
compared a triple combination of rifabutin together with a PPI and amoxicillin vs. the
widely used bismuth quadruple regimen [36,51,86,91]. As an example, in the study by
Perri et al. [36], side effects were less frequent in rifabutin-treated patients than in those on
bismuth quadruple therapy. Thus, approximately 15% of patients on quadruple therapy
experienced moderate to severe side effects, and 6% had to discontinue treatment. In
contrast, in the rifabutin-treated groups, no moderate or severe side effects were observed,
and no patients discontinued treatment because of side effects.
Other studies compared rifabutin treatment with other regimens different to the
bismuth quadruple therapy. Miehlke et al. [51] compared rifabutin-based triple therapy vs.
high-dose dual therapy for rescue treatment of H. pylori. Patients were randomized to a PPI,
rifabutin, and amoxicillin for 7 days, or to a PPI and amoxicillin 1000 mg/8 h for 14 days.
Premature discontinuation of treatment occurred in 2% and 5% of patients, respectively.
Finally, one study directly compared rifabutin to levofloxacin as third-line therapy for
H. pylori, and adverse events were reported in 60% and 50% of cases, respectively [89].
9. Limitations of Rifabutin Treatment
Several concerns remain regarding rifabutin for H. pylori eradication treatment. First,
this drug is quite expensive. Second, as previously reviewed, severe leucopenia has been
reported in some (although exceptional) cases. Finally, although an argument raised
consistently against the wider use of rifabutin is the concern regarding propagation of
resistance, especially in mycobacterial species, it should be taken into account that the
major use of rifabutin is for treatment of tuberculosis and other mycobacteria especially in
the setting of immunodeficiency or HIV infection [39]. Acquired rifabutin resistance has
been noted in these cohorts, but only when associated with CD4 counts <100 cells/mm3
and when intermittent dosing is used [132]. Even in the setting of prolonged tuberculosis
treatment, continuous daily rifabutin has led to negligible rates of resistance [132,133].
Moreover, no reports have yet to definitively link rifabutin resistance with short course
treatment of rifabutin for H. pylori or other non-mycobacterial indications [24,39].
10. Conclusions
Even with the current most effective treatment regimens, a relevant proportion of
patients will fail to eradicate H. pylori infection. Nowadays, apart from having to know
first-line eradication regimens well, we must also be prepared to face treatment failures. In
this context, rifabutin has potential utility against H. pylori as this antibiotic shows good
in vitro activity against this microorganism, and the prevalence rate of rifabutin resistance
is very low (less than 1%).
Mean H. pylori eradication rate (overall results, by intention-to-treat analysis) with
rifabutin-containing regimens was 73%. Respective cure rates for second-, third-, fourth-,
and fifth-line rifabutin therapies, were 79%, 69%, 69%, and 72%, respectively. Almost all
studies administered rifabutin 300 mg/day for treating H. pylori infection, which seems to
be more effective than 150 mg/day. The ideal length of treatment for rifabutin regimen
remains unclear, but 10- to 12-day regimens are usually recommended.
The mean rate of adverse effects to rifabutin treatment in H. pylori studies was rel-
atively low (15%), and severe adverse events are exceptional. Myelotoxicity is the most
significant adverse event of rifabutin during H. pylori therapy, although this complication
was rare, always reversible, and without clinical consequences (such as infection) in the
setting of H. pylori treatment.
Regarding the positioning of rifabutin regimens, clinical experience with rifabutin
for treatment of H. pylori infection has focused mainly on patients in whom one or more
courses of anti-H pylori treatment have previously failed. Since resistance to rifabutin
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is practically inexistent, and that rifabutin therapy is highly effective even in patients
with primary resistance to clarithromycin, metronidazole, and levofloxacin, rifabutin use
in an empirical manner as “rescue” therapy without culture in those patients in whom
these antibiotics have failed, may be suggested. Recent studies have evaluated the role
of rifabutin in H. pylori treatment naïve patients, with encouraging results. Nevertheless,
the consideration of rifabutin as a novel first-line treatment option for H. pylori infection
should be carefully weighed against concerns regarding microbial resistance, treatment cost
(rifabutin is quite expensive), and the availability and effectiveness of alternative drugs.
At present, therefore, rifabutin is generally restricted to patients where previous (usu-
ally multiple) eradication regimens with key antibiotics such as amoxicillin, clarithromycin,
metronidazole, tetracycline, and levofloxacin have failed. Thus, it may be suggested
that the position of rifabutin in the algorithm of H. pylori treatment may be, usually, at
a fourth-line rescue regimen. Nevertheless, rifabutin could be also recommended in an
earlier scenario, for example, as second- or third-line treatment, if antibiotic resistance (for
example to quinolones) is demonstrated or suspected; or even as a first-line treatment in
regions with high clarithromycin, metronidazole, and levofloxacin resistance if bismuth is
unavailable.
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